What are the treatment options for restless legs syndrome?

Restless legs syndrome (RLS) is a neurological sensorimotor disorder characterized by an irresistible urge to move the legs, typically accompanied by uncomfortable or unpleasant sensations—often described as crawling, creeping, pulling, or tingling—worsening during periods of rest or inactivity and partially or fully relieved by movement. Management is individualized and depends on symptom severity, frequency, impact on sleep and quality of life, and presence of underlying contributors.

First-line approaches include identifying and correcting modifiable risk factors: iron deficiency (particularly low serum ferritin < 75 µg/L) is strongly associated with RLS and should be evaluated with serum ferritin and iron studies; oral iron supplementation—often with vitamin C to enhance absorption—is recommended when deficiency is confirmed. Other reversible contributors include renal insufficiency, pregnancy (especially third trimester), peripheral neuropathy, certain medications (e.g., selective serotonin reuptake inhibitors, antipsychotics, antihistamines), and lifestyle factors such as caffeine, alcohol, and nicotine use—all warranting careful review and adjustment where appropriate.

For patients with moderate-to-severe symptoms or those unresponsive to conservative measures, pharmacologic therapy is indicated. Dopamine agonists—such as pramipexole, ropinirole, and rotigotine—are FDA-approved for RLS and remain first-line drug treatments due to their efficacy in reducing sensory discomfort and motor restlessness. However, long-term use carries risks of augmentation (earlier onset, increased intensity, or spread of symptoms) and impulse control disorders, necessitating regular clinical monitoring. Alpha-2-delta ligands—including gabapentin enacarbil (FDA-approved), gabapentin, and pregabalin—are increasingly preferred, especially in patients with comorbid insomnia or neuropathic pain, due to lower augmentation risk and favorable tolerability.

In refractory cases or when contraindications exist, alternative agents may be considered off-label, including low-potency opioids (e.g., tramadol, oxycodone–naloxone) for severe, treatment-resistant RLS, or benzodiazepines (e.g., clonazepam) for sleep disruption—though these are not disease-modifying and carry risks of dependence and cognitive side effects. Nonpharmacologic strategies—including consistent sleep hygiene, moderate evening exercise, leg massage, warm baths, and pneumatic compression devices—may provide adjunctive benefit, particularly in mild cases.

Long-term management emphasizes shared decision-making, periodic reassessment of symptom burden and treatment response, and vigilance for complications such as sleep fragmentation, daytime fatigue, depression, and impaired occupational or social functioning. Referral to a neurologist or sleep specialist is warranted for diagnostic uncertainty, atypical features, or inadequate response to standard therapies.